Literature DB >> 21779673

[Scleral injury caused by needling revision with adjunctive mytomicin-C: case report].

Heloisa Andrade Maestrini1, Thatiana Almeida Pereira Fernandes, Hérika Danielle De Miranda Santos Matoso, Willer Otávio Guimarães Amaral, Angela Andrade Maestrini.   

Abstract

A 70-year-old female patient underwent cataract and glaucoma surgery on her left eye in 1996. Eleven years later, we performed two bleb needling revisions with adjunctive mytomicin-C, in order to decrease an uncontrolled intraocular pressure of 32 mmHg. After the second needling, she developed severe overfiltration, with flat anterior chamber, choroidal effusion, and impending corneal decompensation. Conservative treatment with cycloplegic and corticosteroid eye drops, acetazolamide and therapeutic contact lenses was unsuccessfully tried. Anterior chamber reformation was successively tried with air, 4% ophthalmic viscosurgical device and 1% sodium hyaluronate, with only temporary results. Compressive sutures above the overfiltering bleb were applied, unsuccessfully. In order to avoid additional corneal endothelium damage, a surgical bleb revision was performed and revealed a large area of ciliary body and choroidal exposure under the conjunctiva. It was covered by a donor scleral patch graft providing successful resolution. Nevertheless, we had to reintroduce hypotensive eyedrops. While bleb needling is a relatively safe and effective procedure, ophthalmologists should be aware of the possibility of potentially serious complications, such as in this case report.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21779673     DOI: 10.1590/s0004-27492011000200015

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  1 in total

1.  Early transconjunctival needling revision with 5-fluorouracil versus medical treatment in encapsulated blebs: a 12-month prospective study.

Authors:  Ricardo Suzuki; Remo Susanna
Journal:  Clinics (Sao Paulo)       Date:  2013-10       Impact factor: 2.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.